<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921802</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-Celgene-JP-PMS-001a</org_study_id>
    <nct_id>NCT02921802</nct_id>
  </id_info>
  <brief_title>A Study of Special Use Results Surveillance of Revlimid 5mg Capsules</brief_title>
  <official_title>Revlimid 5 mg Capsules Special Use-results Surveillance (All-case Surveillance)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To understand the safety and efficacy of RevlimidÂ® 5 mg Capsules (hereinafter referred to as
      Revlimid) in all patients who are treated with it under the actual condition of use pursuant
      to the conditions of approval.

        1. Planned registration period This period started on the date of initial marketing of
           Revlimid and will end at the time when the planned number of patients to be enrolled is
           reached.

        2. Planned surveillance period This period started on the date of initial marketing of
           Revlimid and will end on the day when the approval condition related to all-case
           surveillance is terminated.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 20, 2010</start_date>
  <completion_date type="Anticipated">June 19, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 19, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of participants with adverse events for 6 month treatment</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4626</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Patients who received Revlimid</arm_group_label>
    <description>Among relapsed or refractory multiple myeloma and Myelodysplastic syndrome (MDS) with a deletion 5q cytogenetic abnormality patients, all patients who received Revlimid will be targeted in this surveillance.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Among relapsed or refractory multiple myeloma and Myelodysplastic syndrome (MDS) with a
        deletion 5q cytogenetic abnormality patients, all patients who received Pomalyst will be
        targeted in this surveillance.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Among relapsed or refractory multiple myeloma and Myelodysplastic syndrome (MDS) with
             a deletion 5q cytogenetic abnormality patients, all patients who received Revlimid
             will be targeted in this surveillance.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoko Matsui</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shinko Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>651-0072</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2016</study_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Teratogenicity</keyword>
  <keyword>Thrombocytopenia and haemorrhage</keyword>
  <keyword>Neutropenia and infection</keyword>
  <keyword>Venous thromboembolism</keyword>
  <keyword>Allergic reactions</keyword>
  <keyword>Diarrhoea or constipation</keyword>
  <keyword>Peripheral neuropathy</keyword>
  <keyword>Cardiac failure</keyword>
  <keyword>Arrhythmia</keyword>
  <keyword>Renal failure</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Interstitial lung disease</keyword>
  <keyword>Tumour lysis syndrome</keyword>
  <keyword>Transformation from myelodysplastic syndrome to acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

